Gastric cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 33(2022), 10 vom: 26. Okt., Seite 1005-1020 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lordick, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diagnosis |
|---|
| Anmerkungen: |
Date Completed 17.10.2022 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2022.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344342727 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344342727 | ||
| 003 | DE-627 | ||
| 005 | 20231226022539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2022.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344342727 | ||
| 035 | |a (NLM)35914639 | ||
| 035 | |a (PII)S0923-7534(22)01851-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lordick, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gastric cancer |b ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2022 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ESMO Clinical Practice Guideline | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a follow-up | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Carneiro, F |e verfasserin |4 aut | |
| 700 | 1 | |a Cascinu, S |e verfasserin |4 aut | |
| 700 | 1 | |a Fleitas, T |e verfasserin |4 aut | |
| 700 | 1 | |a Haustermans, K |e verfasserin |4 aut | |
| 700 | 1 | |a Piessen, G |e verfasserin |4 aut | |
| 700 | 1 | |a Vogel, A |e verfasserin |4 aut | |
| 700 | 1 | |a Smyth, E C |e verfasserin |4 aut | |
| 700 | 0 | |a ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 33(2022), 10 vom: 26. Okt., Seite 1005-1020 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:10 |g day:26 |g month:10 |g pages:1005-1020 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2022.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 10 |b 26 |c 10 |h 1005-1020 | ||